Prominent changes in blood coagulation of patients with SARS-CoV-2 infection
By Huan Han, Lan Yang, R. Liu, Fang Liu, Kailang Wu, Jie Li, Xinghui Liu, Chengliang Zhu. Clinical Chemistry and Laboratory Medicine, 2020
1,144 citations recorded by the source corpus.
Abstract Background As the number of patients increases, there is a growing understanding of the form of pneumonia sustained by the 2019 novel coronavirus (SARS-CoV-2), which has caused an outbreak in China. Up to now, clinical features and treatment of patients infected with SARS-CoV-2 have been reported in detail. However, the relationship between SARS-CoV-2 and coagulation has been scarcely addressed. Our aim is to investigate the blood coagulation function of patients with SARS-CoV-2 infection. Methods In our study, 94 patients with confirmed SARS-CoV-2 infection were admitted in Renmin Hospital of Wuhan University. We prospectively collect blood coagulation data in these patients and in 40 healthy controls during the same period. Results Antithrombin values in patients were lower than that in the control group (p < 0.001). The values of D-dimer, fibrin/fibrinogen degradation products (FDP), and fibrinogen (FIB) in all SARS-CoV-2 cases were substantially higher than those in healthy controls. Moreover, D-dimer and FDP values in patients with severe SARS-CoV-2 infection were higher than those in patients with milder forms. Compared with healthy controls, prothrombin time activity (PT-act) was lower in SARS-CoV-2 patients. Thrombin time in critical SARS-CoV-2 patients was also shorter than that in controls. Conclusions The coagulation function in patients with SARS-CoV-2 is significantly deranged compared with healthy people, but monitoring D-dimer and FDP values may be helpful for the early identification of severe cases.
Subfields: Infectious Diseases, Oncology
View Paper: https://www.semanticscholar.org/paper/eab839fe51d53334a29ec2fd0be3a1c1649ae1ea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up (2020, background): “related to other tests are less certain and often contradictory (24,25).”
- Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past (2020, background): “commonly affected (∼60% of cases) with a median age of approximately 50 years [1,4,5].”
- Hematological findings and complications of COVID‐19 (2020, result): “05 for both comparisons).(39) All the above indicate that D-dimer elevation and DIC may be common in patients with severe form of COVID-19 infection, a fact that, despite methodological limitations, became evident in a metaanalysis of four published studies (Table 4).”
- Neutrophil extracellular traps in COVID-19. (2020, background): “Indeed, many patients have a profile to suggest a prothrombotic diathesis including high levels of fibrin degradation products (D-dimer), elevated fibrinogen levels, and low antithrombin levels 24, 25 .”
- Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy (2020, neutral): “(3) (4) (5) (6) (7) (8) Signs of myocardial injury are present in at least one quarter of severe cases.”